Clinical Study
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
Table 3
Adverse events of RAK and RBAK therapies for Helicobacter pylori eradication.
| Adverse events, n (%) | RAK () | RBAK () | value |
| Abdominal pain | 9 (11.1) | 12 (14.8) | 0.48 | Diarrhea | 14 (17.3) | 11 (13.6) | 0.52 | Constipation | 3 (3.7) | 4 (4.9) | 0.70 | Headache | 3 (3.7) | 1 (1.2) | 0.31 | Anorexia | 1 (1.2) | 1 (1.2) | ā | Nausea | 3 (3.7) | 2 (2.5) | 0.65 | Skin rash | 2 (2.5) | 1 (1.2) | 0.56 | Dizziness | 3 (3.7) | 2 (2.5) | 0.65 | Bad taste | 25 (30.9) | 20 (24.7) | 0.38 | Fatigue | 9 (11.1) | 7 (8.6) | 0.60 | Others | 7 (8.6) | 15 (18.5) | 0.07 | Overall | 41 (50.6) | 41 (50.6) | ā |
|
|